Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05592379 · ClinicalTrials.gov registry record · Phase 1
Consciousness, Psilocybin, and Well-Being
A Phase 1 study, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT05592379: Completed Phase 1 study, sponsored by University of Wisconsin, Madison.
NCT05592379 is a Phase 1 study that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 6 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05592379, a Phase 1 study, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
This study is being done to identify a dosing strategy that will allow IV psilocybin to be administered to sleeping participants without awakening them.
Primary Outcome
Adverse events associated with the administration of a single dose of IV psilocybin administered either alone or in combination with oral clonidine in asleep and awake participants. Adverse event grading will be done using Common Terminology Criteria for Adverse Event (CTCAE)Adverse events will be graded from Grade 1-5 depending on severity. Grade 1 - mild, grade 2 - moderate, grade 3 - severe, grade 4 - Life threatening, grade 5 - Fatal. Adverse events will be collected on an Adverse Event Log
Interventions
- OTHER Saline
- DRUG Psilocybin
- DRUG Clonidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2023-11-07 |
| Est. Completion | 2025-02-19 |
| Phase | Phase 1 |
What the finished NCT05592379 record still lists
NCT05592379 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 3 interventions - of which Saline is the first listed.
NCT05592379 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05592379 about?
NCT05592379 is a clinical study titled "Consciousness, Psilocybin, and Well-Being". This study is being done to identify a dosing strategy that will allow IV psilocybin to be administered to sleeping participants without awakening them.
What is the current status of trial NCT05592379?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2023-11-07. Estimated completion is 2025-02-19.
What interventions are being tested in trial NCT05592379?
The interventions under investigation include: Saline (OTHER), Psilocybin (DRUG), Clonidine (DRUG).
Who is sponsoring clinical trial NCT05592379?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05592379's enrollment target sits among peer trials
6 1974th of 2000 higher than 12 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI